vorinostat
2 clinical trials
8 abstracts
2 indications
Indication
Breast CancerIndication
NeuroblastomaAbstract
Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications.Org: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Clinical trial
A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-06-01
Clinical trial
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2030-09-01
Abstract
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).Org: Curie Institute, Institut de Cancerologie de l'Ouest, Saint-Herblain, France, ICO Institut de Cancerologie de l'Ouest, Drug Development and Innovation Department, Center Georges-Francois Leclerc,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.Org: Moffitt Cancer Center, Duke Cancer Institute,
Abstract
Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors.Org: Anbogen Therapeutics, Anbogen Tharapeutics, TMU Research Center of Drug Discovery,
Abstract
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for human uterine sarcoma cells.Org: Cancer Biology Department, National Cancer Institute, Vilnius, Lithuania, Cairo University, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, University of Chicago,
Abstract
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,